Loading…
Strut Health, LLC received a warning letter for misbranding compounded semaglutide and tirzepatide drug products sold through its website. The company falsely implied it was the compounder of these drugs when it was not, and made misleading claims that the products were "Generic Zepboot" and "Generic Mounjaro," suggesting FDA approval when compounded drugs are not FDA-approved. These violations of the Federal Food, Drug, and Cosmetic Act sections 502(a) and 502(bb) resulted in misbranded drugs being introduced into interstate commerce.